Skip to main
AUPH
AUPH logo

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is projected to experience significant revenue growth, with risk-adjusted product revenues expected to increase from $243.7 million in 2025 to $932.3 million by 2033. Additionally, the company anticipates aritinercept to generate risk-adjusted revenue of $15.4 million in 2030, rising to $281.6 million by 2033, subject to a 20% probability of launch and a peak market penetration rate of 15%. Furthermore, the anticipated impact of the 2024 ACR LN guidelines is expected to catalyze further growth for LUPKYNIS starting in 2027, enhancing the overall outlook for the company's financial trajectory.

Bears say

Aurinia Pharmaceuticals has faced challenges with LUPKYNIS adoption, reflected in slow sales growth that may hinder the company's ability to achieve profitability in the near term. Additionally, the ongoing development of AUR200 comes with substantial R&D costs, which could strain financial resources and delay potential revenue generation. The overall market environment and competition in the biopharmaceutical sector may further exacerbate these financial pressures, leading to a cautious outlook on the company's stock.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 4 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.